Expression pattern of GPR30 in endometriosis

EP Samartzis, N Samartzis, Aurelia Noske, André Fedier, Rosmarie Caduff, D J Fink, P Imesch
In: Geburtshilfe und Frauenheilkunde · 2011 · vol. 71(05) · doi:10.1055/s-0031-1280499 · W2329374199
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This study investigated the expression pattern of G-protein coupled receptor 30 (GPR30) in endometriosis due to its role in estrogen action and proliferative effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-11 · read from full text ⓘ

This study investigated the expression pattern of G-protein coupled receptor 30 (GPR30) in endometriotic tissues compared to normal eutopic endometrium. Researchers analyzed a tissue microarray containing samples from premenopausal women, including ovarian, peritoneal, and deep infiltrating lesions, using immunohistochemistry for GPR30 alongside estrogen and progesterone receptors. The results demonstrated that high cytoplasmic GPR30 expression was present in half of the endometriotic epithelial cells but absent in all control eutopic endometrial cells, with the strongest expression observed in ovarian endometriosis. The authors concluded that this overexpression suggests GPR30 may contribute to hormonal regulation and cell proliferation within endometriotic lesions, potentially serving as a novel therapeutic target. This paper is centrally about endometriosis — specifically examining the molecular expression of GPR30 across different lesion types to understand its role in disease pathogenesis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction: G-protein coupled receptor 30 (GPR30) is a seven-transmembrane receptor suggested to be part of non-genomic estrogen responses that can, in contrast to the classic or genomic mode of ER action, occur rapidly within minutes. GPR30 mediated estrogen action is involved in multiple physiological processes, as well as pathological processes, as for example the proliferative effects of estrogen and tamoxifen in endometrial cancer cells. Since Estrogen action plays a key role in endometriosis and is partly mediated by GPR30 in a various number of physiological and pathological processes, the investigation of its expression in endometriosis could be of particular interest.
Full text 1,882 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Introduction

G-protein coupled receptor 30 (GPR30) is a seven-transmembrane receptor suggested to be part of non-genomic estrogen responses that can, in contrast to the classic or genomic mode of ER action, occur rapidly within minutes. GPR30 mediated estrogen action is involved in multiple physiological processes, as well as pathological processes, as for example the proliferative effects of estrogen and tamoxifen in endometrial cancer cells. Since Estrogen action plays a key role in endometriosis and is partly mediated by GPR30 in a various number of physiological and pathological processes, the investigation of its expression in endometriosis could be of particular interest.

Methods

Immunohistochemical analysis for GPR30, ER-alpha, ER-beta and PR was performed on a tissue microarray including 74 endometriotic tissue samples of premenopausal women with following localisations (27 ovarian, 19 peritoneal, 28 deep infiltrating lesions). 30 samples of eutopic endometrial tissue served as a control in the same TMA.

Results

High cytoplasmic GPR30 expression was found in 50% (n=30/60) of endometriotic epithelial cells, but in none (0/30) of the eutopic endometrial epithelial cells (p<0.001). Furthermore cytoplasmic GPR30 was expressed significantly stronger in ovarian endometriosis (6/20, 70%; p=0.01) than in peritoneal (9/18, 50%) and deep infiltrating endometriosis (15/22, 31.8%). Nuclear GPR30 expression did not show a significant difference in endometrial lesion to normal endometrium.

Conclusion

Nongenomic GPR30 is known to be part of a signaling pathway inducing cell proliferation and migration. Its overexpression in endometriotic lesion could play an additional role in the hormonal regulation of endometriosis an could represent a novel therapeutical target.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
unpaywall
last seen: 2026-10-01T06:38:16.588661+00:00
License: CC0 · commercial use OK